• Explore /
  • Poster
  • / MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R<sup>2</sup>) induction followed by maintenance R<sup>2</sup> followed by lenalidomide versus R<sup>2</sup> induction followed by rituximab (R) maintenance.

MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance.

Abstract Poster

Authors

null

David Jacob Andorsky

Rocky Mountain Cancer Centers, Boulder, CO

David Jacob Andorsky , Paula J. Franson , Jorge L Mouro , Jiahui Li , Kenneth A. Foon , Jeff Porter Sharman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT01996865

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS8606)

DOI

10.1200/jco.2015.33.15_suppl.tps8606

Abstract #

TPS8606

Poster Bd #

421b

Abstract Disclosures

Similar Posters

First Author: David J Andorsky

First Author: Laurie Helen Sehn

First Author: Ki Hyun Kim

First Author: David Andorsky